



Financial Tear Sheet

Corporate Profile

Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, for the treatment of sickle cell disease and idiopathic pulmonary fibrosis.

Primary IR Contact

Myesha Lacy

Phone: 650-351-4730

E-mail: investor@gbt.com


Stock Performance

GBT (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	\$40.51
Change (%)	▼ 0.85 (2.03%)
Volume	251,996
52 Week Low	\$24.03
Market Cap	\$2,142,998,856
Rolling EPS	-3.03
PE Ratio	0

Shares Outstanding 51,825,849

Data as of 06/22/18 1:05 p.m. ET



Recent Headlines & Events

06/15/18

[GBT Announces New Phase 2a Voxelotor Data in Adolescents with Sickle Cell Disease \(SCD\) at 23rd European Hematology Association \(EHA\) Congress](#)

06/08/18

[GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease \(SCD\) Program at Foundation for Sickle Cell Disease Research's 12th Annual Symposium](#)

06/05/18

[GBT Announces New Employment Inducement Grants](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
06/15/18	<u>8-K</u>
05/21/18	<u>4</u>
05/07/18	<u>10-Q</u>
05/07/18	<u>8-K</u>

Corporate Governance

[Ted W. Love, M.D.](#) Chief Executive Officer

[Jeffrey Farrow](#) Chief Financial Officer

[Jung E. Choi](#) Chief Business and Strategy Officer

[Tricia Suvari](#) Chief Legal Officer

[Hing Sham, Ph.D.](#) Senior Vice President, Research

[Peter Radovich](#) Vice President, Program Leadership and Business Strategy

Data provided by Nasdaq. Minimum 15 minutes delayed.